Medicinal Cannabis Clinical Trial Shows Insomnia Symptom Improvement
Its findings suggest that ZTL-101 cannabis treatment is safe and effective for chronic insomnia.
Category: Emerging Compounds
Emerging Compounds
LatestEmerging Compounds
Latest
FDA Accepts NDA for Low-Sodium Alternative to Xyrem for Narcolepsy
The FDA accepted for filing with Priority Review the Jazz Pharmaceuticals plc's NDA seeking marketing approval for JZP-258, an investigational medicine for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Emerging Compounds
Popular
Embrace by Empatica Smart Watch Cleared by FDA for Use in Neurology
Empatica Inc has received clearance from the US Food and Drug Administration (FDA) for Embrace,...
Survey: Your Narcolepsy Patients Don’t Necessarily Agree That Their Symptoms Are Controlled
Investigators surveyed health care providers as well as people with narcolepsy, and multiple...
Read MoreJazz Pharmaceuticals’ Sunosi Gets EU Marketing Authorization for Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea
The European Commission has approved Jazz Pharmaceuticals plc’s Sunosi (solriamfetol) to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adults with narcolepsy (with or without cataplexy) or...
Read More
FDA Approves Orexin Receptor Antagonist for Insomnia
The US Food and Drug Administration (FDA) has approved the new drug application for Eisai Co...
Read MoreEisai Inc Announces US Approval for Insomnia Drug
Japan-based drugmaker Eisai Co’s US subsidiary announced on Sunday that it had received approval from the US Food and Drug Administration for its insomnia treatment in adult patients. The agency approved the drug, Dayvigo,...
Read More
WAKIX (Pitolisant) Safety and Efficacy Data Published in SLEEP
Data from two clinical studies evaluating the long-term safety and efficacy, as well as the human...
Read More
Avadel Meets Revised Target Enrollment for Once-nightly Sodium Oxybate Phase 3 Study for Narcolepsy
Avadel Pharmaceuticals plc, a company focused on developing FT218, an investigational once-nightly...
Read MoreWhen Cannabis Is Readily Available, Other OTC Sleep Aid Sales Decline
A recent study, “Using Recreational Cannabis to Treat Insomnia: Evidence from Over-The-Counter Sleep Aid Sales in Colorado,” published in the journal Complementary Therapies in Medicine, uses Universal Product Code...
Read MoreClinical Challenges: Cannabis Gains Ground as Sleep Aid
Efficacy of CBD, THC products to treat sleep disorders remains largely untested, reports MedPage Today.”I believe it is a significant overreach to say that these studies show that [THC products] are useful in the treatment...
Read More
Dronabinol-CannAmide Combo Drug Shows Promising Results for Sleep Apnea in Phase IIa Clinical Study
Therapix Biosciences Ltd, a specialty, clinical-stage pharmaceutical company focusing on the...
Read More
First Patient Dosed in Phase 2 Study of Potential Molecule for Insomnia Associated with Alcohol Cessation
Purdue Pharma LP operating subsidiary Imbrium Therapeutics LP announced the first dose...
Read MoreAxsome Completes Patient Enrollment in Phase 2 Trial of AXS-12 in Narcolepsy
Axsome Therapeutics Inc has completed of patient enrollment in the CONCERT study, a Phase 2, randomized, double-blind, placebo-controlled, crossover, trial of AXS-12 in patients with narcolepsy. AXS-12 (reboxetine) is a novel,...
Read More
A Biopharma Company Explores a Glutamate Receptor Modulator’s Impact on Sleep Quality
Recently published preclinical data about an N-methyl-D-aspartate (NMDA) receptor...
Read More
Are You Missing the Outcomes that Matter to Your Insomnia Patients?
A survey by pharmaceutical company Eisai Inc explored the impact of insomnia or sleeping...
Read More
In Phase 3, Low Sodium Alternative to Xyrem Achieves Primary and Secondary Endpoints
Positive data from the Phase 3 study of Jazz Pharmaceuticals plc’s investigational medicine,...
Read MoreAvadel Gets FDA OK to Reduce Sample Size for Once-nightly Sodium Oxybate Phase 3 Study
Avadel Pharmaceuticals plc, a company focused on developing once-nightly sodium oxybate, FT218, for narcolepsy, reports that the U.S. Food and Drug Administration (FDA) has agreed to the company’s proposed amendments to...
Read More